Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at $4,031,729.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Halozyme Therapeutics Stock Up 0.5 %
HALO stock opened at $59.42 on Friday. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $60.15. The company’s 50 day simple moving average is $53.14 and its 200-day simple moving average is $44.66. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The firm has a market capitalization of $7.56 billion, a P/E ratio of 24.65, a P/E/G ratio of 0.56 and a beta of 1.27.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. During the same quarter in the previous year, the business earned $0.68 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on HALO
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in HALO. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics during the fourth quarter valued at approximately $1,030,000. Mirae Asset Global Investments Co. Ltd. grew its position in Halozyme Therapeutics by 0.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 76,472 shares of the biopharmaceutical company’s stock worth $2,826,000 after acquiring an additional 674 shares in the last quarter. Louisiana State Employees Retirement System bought a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $1,371,000. Cornercap Investment Counsel Inc. grew its position in Halozyme Therapeutics by 130.9% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 28,085 shares of the biopharmaceutical company’s stock worth $1,038,000 after acquiring an additional 15,924 shares in the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Halozyme Therapeutics in the fourth quarter worth approximately $196,000. 97.79% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Further Reading
- Five stocks we like better than Halozyme Therapeutics
- Industrial Products Stocks Investing
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Stock Splits, Do They Really Impact Investors?
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- The 3 Best Retail Stocks to Shop for in August
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.